Micallef Jacob Vincent

SEC source: 0001477932-26-001488 · form4.xml · nonDerivative · entry 1

Micallef Jacob Vincent · CIK 0001651671 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 572,179

F1 · shares: Represents the aggregate number of shares of common stock retained by VolitionRx for cancellation to satisfy the tax withholding obligations of the reporting person upon settlement of 11,800 restricted stock units. No shares were sold by the reporting person or VolitionRx in such transaction.

SEC source: 0001477932-26-001096 · form4.xml · nonDerivative · entry 1

Micallef Jacob Vincent · CIK 0001651671 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 577,489

F1 · shares: On February 26, 2026, the reporting person was awarded 149,000 restricted stock units ("RSUs") under the Issuer's 2024 Stock Incentive Plan in lieu of cash compensation that would otherwise have been owed to the reporting person. The RSUs will be earned in twelve approximately equal monthly installments commencing on March 1, 2026. Once earned, they will remain subject to additional time-based vesting in a single installment on February 26, 2027, and are generally subject to continued service by the reporting person throughout each applicable earning and vesting date. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of RSUs that have been earned and vested as of the vesting date.

SEC source: 0001477932-26-000362 · form4.xml · nonDerivative · entry 1

Micallef Jacob Vincent · CIK 0001651671 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 428,489

F1 · shares: On March 17, 2025, the reporting person was awarded 118,000 restricted stock units ("RSUs") under the Issuer's 2024 Stock Incentive Plan, subject to vesting upon the achievement of certain corporate performance goals on or prior to June 30, 2025 and December 31, 2025 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 35,400 RSUs vesting. The RSUs are further subject to a 3-year time-based vesting schedule, vesting in three equal installments of 11,800 units on each of March 17, 2026, 2027 and 2028, respectively. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of RSUs that have vested. The rights with respect to the remaining 82,600 RSUs did not vest and were cancelled on June 30, 2025 and January 22, 2026, respectively.

SEC source: 0001477932-25-007400 · form4.xml · nonDerivative · entry 1

Micallef Jacob Vincent · CIK 0001651671 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 393,089

F1 · shares: Represents the aggregate number of shares of common stock retained by VolitionRx for cancellation to satisfy the tax withholding obligations of the reporting person upon settlement of 13,000 restricted stock units. No shares were sold by the reporting person or VolitionRx in such transaction.

SEC source: 0001477932-25-007231 · form4.xml · nonDerivative · entry 1

Micallef Jacob Vincent · CIK 0001651671 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 398,939

F1 · shares: Represents the aggregate number of shares of common stock retained by VolitionRx for cancellation to satisfy the tax withholding obligations of the reporting person upon settlement of 12,375 restricted stock units. No shares were sold by the reporting person or VolitionRx in such transaction.

SEC source: 0001477932-25-004365 · form4.xml · nonDerivative · entry 1

Micallef Jacob Vincent · CIK 0001651671 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 404,507

F1 · shares: Represents the aggregate number of shares of common stock retained by VolitionRx for cancellation to satisfy the tax withholding obligations of the reporting person upon settlement of 47,837 restricted stock units that were awarded in lieu of cash compensation that would otherwise have been owed to the reporting person. No shares were sold by the reporting person or VolitionRx in such transaction.

SEC source: 0001477932-25-003965 · form4.xml · nonDerivative · entry 1

Micallef Jacob Vincent · CIK 0001651671 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 426,033

SEC source: 0001477932-25-003314 · form4.xml · nonDerivative · entry 1

Micallef Jacob Vincent · CIK 0001651671 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 376,033

F1 · shares: Represents the aggregate number of shares of common stock retained by VolitionRx for cancellation to satisfy the tax withholding obligations of the reporting person upon settlement of 40,709 restricted stock units that were awarded in lieu of cash compensation that would otherwise have been owed to the reporting person. No shares were sold by the reporting person or VolitionRx in such transaction.

SEC source: 0001477932-25-000610 · form4.xml · derivative · entry 2

Micallef Jacob Vincent · CIK 0001651671 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 50,000

Underlying: Common Stock · 50,000 shares

Expires 2029-02-11

F1 · kind: The reported transaction involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on February 11, 2019, vested in full and were exercisable at 12 months from the date of grant, and were exercisable for five years from the date first exercisable. The "replacement" options are fully-vested and expire on February 11, 2029 (ten years from the original date of grant).

F1 · price: The reported transaction involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on February 11, 2019, vested in full and were exercisable at 12 months from the date of grant, and were exercisable for five years from the date first exercisable. The "replacement" options are fully-vested and expire on February 11, 2029 (ten years from the original date of grant).

SEC source: 0001477932-25-000610 · form4.xml · derivative · entry 1

Micallef Jacob Vincent · CIK 0001651671 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 50,000 shares

Expires 2025-02-11

F1 · kind: The reported transaction involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on February 11, 2019, vested in full and were exercisable at 12 months from the date of grant, and were exercisable for five years from the date first exercisable. The "replacement" options are fully-vested and expire on February 11, 2029 (ten years from the original date of grant).

F1 · price: The reported transaction involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on February 11, 2019, vested in full and were exercisable at 12 months from the date of grant, and were exercisable for five years from the date first exercisable. The "replacement" options are fully-vested and expire on February 11, 2029 (ten years from the original date of grant).

SEC source: 0001477932-24-007970 · form4.xml · nonDerivative · entry 1

Micallef Jacob Vincent · CIK 0001651671 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 394,352

F1 · shares: Acquired at the offering price in the registered direct offering of Common Stock by VolitionRx.

SEC source: 0001477932-24-006281 · form4.xml · nonDerivative · entry 1

Micallef Jacob Vincent · CIK 0001651671 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 350,661

F1 · shares: Represents the aggregate number of shares of common stock retained by VolitionRx for cancellation to satisfy the tax withholding obligations of the reporting person upon settlement of 13,000 restricted stock units. No shares were sold by the reporting person or VolitionRx in such transaction.

SEC source: 0001477932-24-006101 · form4.xml · nonDerivative · entry 1

Micallef Jacob Vincent · CIK 0001651671 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 355,861

F1 · shares: Represents the aggregate number of shares of common stock retained by VolitionRx for cancellation to satisfy the tax withholding obligations of the reporting person upon settlement of 12,375 restricted stock units. No shares were sold by the reporting person or VolitionRx in such transaction.

SEC source: 0001477932-24-005506 · form4.xml · nonDerivative · entry 1

Micallef Jacob Vincent · CIK 0001651671 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 360,811

F1 · shares: On September 1, 2024, the reporting person was awarded 47,837 restricted stock units ("RSUs") under the Issuer's 2015 Stock Incentive Plan in lieu of cash compensation that would otherwise have been owed to the reporting person. The RSUs partially vest in three installments of 15,946 units, 15,946 units, and 15,945 units on each of September 1, 2024, October 1, 2024 and November 1, 2024, respectively, are also subject to further time-based vesting in a single installment on June 1, 2025, and are generally subject to continued service throughout each applicable vesting date. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of RSUs that have vested.

SEC source: 0001477932-24-005025 · form4.xml · nonDerivative · entry 1

Micallef Jacob Vincent · CIK 0001651671 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 312,974

F1 · shares: On Sept 28, 2023, the reporting person was awarded 55,000 restricted stock units ("RSUs") under the Issuer's 2015 Stock Incentive Plan, subject to vesting upon the achievement of certain corporate performance goals on or prior to Dec 31, 2023 and June 30, 2024 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 13,750 RSUs vesting. The RSUs are further subject to a 3-year time-based vesting schedule, vesting in three installments of 4,583 units, 4,583 units, and 4,584 units on each of Sept 28, 2024, 2025 and 2026, respectively. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of RSUs that have vested. As reported in Jan 2024, the rights with respect to 23,375 RSUs subject to the award previously vested and remain subject to time-based vesting. The rights with respect to the remaining 17,875 RSUs did not vest and were cancelled on August 15, 2024.

SEC source: 0001477932-24-003484 · form4.xml · nonDerivative · entry 1

Micallef Jacob Vincent · CIK 0001651671 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 299,224

F1 · shares: On June 1, 2024, the reporting person was awarded 40,709 restricted stock units ("RSUs") under the Issuer's 2015 Stock Incentive Plan in lieu of cash compensation that would otherwise have been owed to the reporting person. The RSUs partially vest in three installments of 13,570 units, 13,570 units, and 13,569 units on each of June 1, 2024, July 1, 2024 and August 1, 2024, respectively, are also subject to further time-based vesting in a single installment on May 1, 2025, and are generally subject to continued service throughout each applicable vesting date. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of RSUs that have vested.

SEC source: 0001477932-24-000413 · form4.xml · nonDerivative · entry 1

Micallef Jacob Vincent · CIK 0001651671 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 258,515

F1 · shares: On September 28, 2023, the reporting person was awarded 55,000 restricted stock units ("RSUs") under the Issuer's 2015 Stock Incentive Plan, subject to vesting upon the achievement of certain corporate performance goals on or prior to December 31, 2023 and June 30, 2024 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 23,375 RSUs vesting. The RSUs are further subject to a 3-year time-based vesting schedule, vesting in three installments of 7,792 units, 7,792 units, and 7,791 units on each of September 28, 2024, September 28, 2025 and September 28, 2026, respectively. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of RSUs that have vested.

SEC source: 0001477932-23-006539 · form4.xml · nonDerivative · entry 2

Micallef Jacob Vincent · CIK 0001651671 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Indirect · By Spouse

Disclosed balance after: 55,000

SEC source: 0001477932-23-006539 · form4.xml · nonDerivative · entry 1

Micallef Jacob Vincent · CIK 0001651671 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Indirect · By Spouse

Disclosed balance after: 46,250

SEC source: 0001477932-23-006497 · form4.xml · nonDerivative · entry 1

Micallef Jacob Vincent · CIK 0001651671 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 235,140

SEC source: 0001477932-23-005788 · form4.xml · nonDerivative · entry 1

Micallef Jacob Vincent · CIK 0001651671 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 215,140

F1 · shares: Represents the aggregate number of shares of common stock retained by VolitionRx for cancellation to satisfy the tax withholding obligations of the reporting person upon settlement of 12,062 restricted stock units. No shares were sold by the reporting person or VolitionRx in such transaction.

SEC source: 0001477932-23-005109 · form4.xml · nonDerivative · entry 1

Micallef Jacob Vincent · CIK 0001651671 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 220,567

F1 · shares: On October 4, 2022, the reporting person was awarded 39,000 restricted stock units ("RSUs") under the Issuer's 2015 Stock Incentive Plan, subject to vesting upon the achievement of certain corporate performance goals on or prior to December 31, 2022 and June 30, 2023 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 17,550 RSUs vesting. The RSUs are further subject to a 3-year time-based vesting schedule, vesting in three equal installments of 5,850 units on each of October 4, 2023, October 4, 2024 and October 4, 2025, respectively. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of RSUs that have vested. As reported in October 2022 and January 2023 respectively, the rights with respect to 6,825 RSUs and 14,625 RSUs subject to the award previously vested and remain subject to time-based vesting.

SEC source: 0001477932-23-000268 · form4.xml · nonDerivative · entry 1

Micallef Jacob Vincent · CIK 0001651671 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 203,017

F1 · shares: On October 4, 2022, the reporting person was awarded 39,000 restricted stock units under the Issuer's 2015 Stock Incentive Plan, subject to vesting upon the achievement of certain corporate performance goals on or prior to December 31, 2022 and June 30, 2023 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 14,625 restricted stock units vesting. The restricted stock units are further subject to a 3-year time-based vesting schedule, vesting in three equal installments of 4,875 units on each of October 4, 2023, October 4, 2024 and October 4, 2025, respectively. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. As reported in October 2022, the rights with respect to 6,825 restricted stock units subject to the award previously vested and remain subject to time-based vesting.

SEC source: 0001477932-22-009423 · form4.xml · nonDerivative · entry 2

Micallef Jacob Vincent · CIK 0001651671 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 188,392

SEC source: 0001477932-22-009423 · form4.xml · nonDerivative · entry 1

Micallef Jacob Vincent · CIK 0001651671 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 163,392

SEC source: 0001477932-22-007693 · form4.xml · nonDerivative · entry 1

Micallef Jacob Vincent · CIK 0001651671 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 156,053

F1 · shares: On October 4, 2022, the reporting person was awarded 39,000 restricted stock units under the Issuer's 2015 Stock Incentive Plan, subject to vesting upon the achievement of certain corporate performance goals on or prior to December 31, 2022 and June 30, 2023 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 6,825 restricted stock units vesting. The restricted stock units are further subject to a 3-year time-based vesting schedule, vesting in three equal installments of 2,275 units on each of October 4, 2023, October 4, 2024 and October 4, 2025, respectively. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested.

SEC source: 0001477932-22-007051 · form4.xml · nonDerivative · entry 1

Micallef Jacob Vincent · CIK 0001651671 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · By Spouse

Disclosed balance after: 35,000

SEC source: 0001477932-22-006505 · form4.xml · nonDerivative · entry 1

Micallef Jacob Vincent · CIK 0001651671 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 149,228

SEC source: 0001477932-22-005692 · form4.xml · nonDerivative · entry 1

Micallef Jacob Vincent · CIK 0001651671 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 120,228

F1 · shares: Represents the aggregate number of shares of common stock retained by VolitionRx for cancellation to satisfy the tax withholding obligations of the reporting person upon settlement of 12,063 restricted stock units. No shares were sold by the reporting person or VolitionRx in such transaction

SEC source: 0001477932-22-004661 · form4.xml · derivative · entry 4

Micallef Jacob Vincent · CIK 0001651671 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 44,457

Underlying: Common Stock · 28,898 shares

Expires 2031-08-03

F3 · derivative.exercise_date: On August 3, 2021, the reporting person was granted an option to purchase 44,457 shares of common stock, subject to vesting upon achievement of certain corporate performance goals on or prior to July 1, 2022 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 28,898 shares vesting. The vested shares are further subject to a 2-year time based vesting schedule, vesting in two installments of 14,450 shares and 14,448 shares on each of August 3, 2022 and August 3, 2023, respectively. As reported in April 2022, the rights with respect to the remaining 15,559 shares subject to the award previously vested and remain subject to time-based vesting.

F3 · balance_after: On August 3, 2021, the reporting person was granted an option to purchase 44,457 shares of common stock, subject to vesting upon achievement of certain corporate performance goals on or prior to July 1, 2022 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 28,898 shares vesting. The vested shares are further subject to a 2-year time based vesting schedule, vesting in two installments of 14,450 shares and 14,448 shares on each of August 3, 2022 and August 3, 2023, respectively. As reported in April 2022, the rights with respect to the remaining 15,559 shares subject to the award previously vested and remain subject to time-based vesting.

SEC source: 0001477932-22-004661 · form4.xml · nonDerivative · entry 1

Micallef Jacob Vincent · CIK 0001651671 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 125,053

F1 · shares: On August 3, 2021, the reporting person was awarded 24,125 restricted stock units, subject to vesting upon achievement of certain corporate performance goals on or prior to July 1, 2022 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 15,682 restricted stock units vesting. The restricted stock units are further subject to a 2-year time-based vesting schedule, vesting in two installments of 7,842 units and 7,840 units on each of August 3, 2022 and August 3, 2023, respectively. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. As reported in April 2022, the rights with respect to the remaining 8,443 restricted stock units subject to the award previously vested and remain subject to time-based vesting.

SEC source: 0001477932-22-002183 · form4.xml · derivative · entry 4

Micallef Jacob Vincent · CIK 0001651671 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,559

Underlying: Common Stock · 15,559 shares

Expires 2031-08-03

F3 · derivative.exercise_date: On August 3, 2021, the reporting person was granted an option to purchase 44,457 shares of common stock, subject to vesting upon achievement of certain corporate performance goals on or prior to July 1, 2022 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 15,559 shares vesting. The vested shares are further subject to a 2-year time based vesting schedule, vesting in two installments of 7,779 shares and 7,780 shares on each of August 3, 2022 and August 3, 2023, respectively.

F3 · balance_after: On August 3, 2021, the reporting person was granted an option to purchase 44,457 shares of common stock, subject to vesting upon achievement of certain corporate performance goals on or prior to July 1, 2022 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 15,559 shares vesting. The vested shares are further subject to a 2-year time based vesting schedule, vesting in two installments of 7,779 shares and 7,780 shares on each of August 3, 2022 and August 3, 2023, respectively.

SEC source: 0001477932-22-002183 · form4.xml · nonDerivative · entry 1

Micallef Jacob Vincent · CIK 0001651671 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 109,371

F1 · shares: On August 3, 2021, the reporting person was awarded 24,125 restricted stock units, subject to vesting upon achievement of certain corporate performance goals on or prior to July 1, 2022 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 8,443 restricted stock units vesting. The restricted stock units are further subject to a 2-year time-based vesting schedule, vesting in two installments of 4,221 units and 4,222 units on each of August 3, 2022 and August 3, 2023, respectively. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested.

SEC source: 0001477932-21-007867 · form4.xml · derivative · entry 6

Micallef Jacob Vincent · CIK 0001651671 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 75,000

Underlying: Common Stock · 75,000 shares

Expires 2028-01-23

F3 · kind: The reported transactions involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on January 23, 2018, vested in full and were exercisable at 12 months from the date of grant, and were exercisable for five years from the date first exercisable. The "replacement" options are fully-vested and expire on January 23, 2028 (ten years from the original date of grant).

F3 · price: The reported transactions involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on January 23, 2018, vested in full and were exercisable at 12 months from the date of grant, and were exercisable for five years from the date first exercisable. The "replacement" options are fully-vested and expire on January 23, 2028 (ten years from the original date of grant).

SEC source: 0001477932-21-007867 · form4.xml · derivative · entry 5

Micallef Jacob Vincent · CIK 0001651671 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 75,000 shares

Expires 2024-01-23

F3 · kind: The reported transactions involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on January 23, 2018, vested in full and were exercisable at 12 months from the date of grant, and were exercisable for five years from the date first exercisable. The "replacement" options are fully-vested and expire on January 23, 2028 (ten years from the original date of grant).

F3 · price: The reported transactions involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on January 23, 2018, vested in full and were exercisable at 12 months from the date of grant, and were exercisable for five years from the date first exercisable. The "replacement" options are fully-vested and expire on January 23, 2028 (ten years from the original date of grant).

SEC source: 0001477932-21-007867 · form4.xml · derivative · entry 4

Micallef Jacob Vincent · CIK 0001651671 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,467

Underlying: Common Stock · 3,467 shares

Expires 2027-03-30

F2 · kind: The reported transactions involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on March 30, 2017, vested in full and were exercisable at 12 months from the date of grant, and were exercisable for five years from the date first exercisable. The "replacement" options are fully-vested and expire on March 30, 2027 (ten years from the original date of grant).

F2 · price: The reported transactions involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on March 30, 2017, vested in full and were exercisable at 12 months from the date of grant, and were exercisable for five years from the date first exercisable. The "replacement" options are fully-vested and expire on March 30, 2027 (ten years from the original date of grant).

SEC source: 0001477932-21-007867 · form4.xml · derivative · entry 3

Micallef Jacob Vincent · CIK 0001651671 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 3,467 shares

Expires 2023-03-30

F2 · kind: The reported transactions involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on March 30, 2017, vested in full and were exercisable at 12 months from the date of grant, and were exercisable for five years from the date first exercisable. The "replacement" options are fully-vested and expire on March 30, 2027 (ten years from the original date of grant).

F2 · price: The reported transactions involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on March 30, 2017, vested in full and were exercisable at 12 months from the date of grant, and were exercisable for five years from the date first exercisable. The "replacement" options are fully-vested and expire on March 30, 2027 (ten years from the original date of grant).

SEC source: 0001477932-21-007867 · form4.xml · derivative · entry 2

Micallef Jacob Vincent · CIK 0001651671 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 125,000

Underlying: Common Stock · 125,000 shares

Expires 2026-04-15

F1 · kind: The reported transactions involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on April 15, 2016, vested in full and were exercisable at 12 months from the date of grant, and were exercisable for five years from the date first exercisable. The "replacement" options are fully-vested and expire on April 15, 2026 (ten years from the original date of grant).

F1 · price: The reported transactions involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on April 15, 2016, vested in full and were exercisable at 12 months from the date of grant, and were exercisable for five years from the date first exercisable. The "replacement" options are fully-vested and expire on April 15, 2026 (ten years from the original date of grant).

SEC source: 0001477932-21-007867 · form4.xml · derivative · entry 1

Micallef Jacob Vincent · CIK 0001651671 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 125,000 shares

Expires 2022-04-15

F1 · kind: The reported transactions involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on April 15, 2016, vested in full and were exercisable at 12 months from the date of grant, and were exercisable for five years from the date first exercisable. The "replacement" options are fully-vested and expire on April 15, 2026 (ten years from the original date of grant).

F1 · price: The reported transactions involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on April 15, 2016, vested in full and were exercisable at 12 months from the date of grant, and were exercisable for five years from the date first exercisable. The "replacement" options are fully-vested and expire on April 15, 2026 (ten years from the original date of grant).

SEC source: 0001477932-21-006595 · form4.xml · derivative · entry 4

Micallef Jacob Vincent · CIK 0001651671 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 70,000

Underlying: Common Stock · 70,000 shares

Expires 2030-04-13

F2 · kind: The reported transactions involved a cancellation and reissuance of outstanding options upon agreement of the reporting person. The "old" options were originally granted on April 13, 2020 and vested in full at 12 months from the date of grant, and were exercisable until April 13, 2026. The "replacement" options are fully-vested on the date of grant and have an expiration date of April 13, 2030.

SEC source: 0001477932-21-006595 · form4.xml · derivative · entry 2

Micallef Jacob Vincent · CIK 0001651671 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 66,533

Underlying: Common Stock · 66,533 shares

Expires 2027-03-30

F1 · kind: The reported transactions involved a cancellation and reissuance of outstanding options upon agreement of the reporting person. The "old" options were originally granted on December 16, 2019, vested in full on the date of grant, and were exercisable until March 30, 2023. The "replacement" options are fully-vested on the date of grant and have an expiration date of March 30, 2027.

SEC source: 0001078782-21-000678 · primary_doc.xml · derivative · entry 2

Micallef Jacob Vincent · CIK 0001651671 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 55,000

Underlying: Common Stock · 55,000 shares

Expires 2025-07-23

F1 · kind: The reported transactions involved an amendment of outstanding options, resulting in the deemed cancellation of the "old' options and the grant of "replacement" options. The "old" options were originally granted on July 23, 2015, vested in full and were exercisable at 6 months from the date of grant, and as amended were exercisable for five years and six months from the date first exercisable. The "replacement" options are fully-vested and expire on July 23, 2025 (ten years from the date of grant).

F1 · price: The reported transactions involved an amendment of outstanding options, resulting in the deemed cancellation of the "old' options and the grant of "replacement" options. The "old" options were originally granted on July 23, 2015, vested in full and were exercisable at 6 months from the date of grant, and as amended were exercisable for five years and six months from the date first exercisable. The "replacement" options are fully-vested and expire on July 23, 2025 (ten years from the date of grant).

SEC source: 0001078782-21-000678 · primary_doc.xml · derivative · entry 1

Micallef Jacob Vincent · CIK 0001651671 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 55,000 shares

Expires 2021-07-23

F1 · kind: The reported transactions involved an amendment of outstanding options, resulting in the deemed cancellation of the "old' options and the grant of "replacement" options. The "old" options were originally granted on July 23, 2015, vested in full and were exercisable at 6 months from the date of grant, and as amended were exercisable for five years and six months from the date first exercisable. The "replacement" options are fully-vested and expire on July 23, 2025 (ten years from the date of grant).

F1 · price: The reported transactions involved an amendment of outstanding options, resulting in the deemed cancellation of the "old' options and the grant of "replacement" options. The "old" options were originally granted on July 23, 2015, vested in full and were exercisable at 6 months from the date of grant, and as amended were exercisable for five years and six months from the date first exercisable. The "replacement" options are fully-vested and expire on July 23, 2025 (ten years from the date of grant).

SEC source: 0001078782-20-001006 · primary_doc.xml · derivative · entry 2

Micallef Jacob Vincent · CIK 0001651671 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 125,000

Underlying: Common Stock · 125,000 shares

Expires 2022-04-15

F1 · kind: The option to purchase an aggregate of 125,000 shares of Common Stock of VolitionRx Limited (the "Issuer"), was granted to Dr. Micallef on April 15, 2016 under the Issuer's 2015 Stock Incentive Plan and transferred to Borlaug Limited ("Borlaug"), a consulting firm, on April 20, 2016. Dr. Micallef is a controlling director of Borlaug and has voting and dispositive control over the Common Stock issuable to Borlaug upon the exercise of the option. The option was then transferred by Borlaug to Dr. Micallef on December 22, 2020.

SEC source: 0001078782-20-001006 · primary_doc.xml · derivative · entry 1

Micallef Jacob Vincent · CIK 0001651671 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · Borlaug Limited

Disclosed balance after: 0

Underlying: Common Stock · 125,000 shares

Expires 2022-04-15

F1 · kind: The option to purchase an aggregate of 125,000 shares of Common Stock of VolitionRx Limited (the "Issuer"), was granted to Dr. Micallef on April 15, 2016 under the Issuer's 2015 Stock Incentive Plan and transferred to Borlaug Limited ("Borlaug"), a consulting firm, on April 20, 2016. Dr. Micallef is a controlling director of Borlaug and has voting and dispositive control over the Common Stock issuable to Borlaug upon the exercise of the option. The option was then transferred by Borlaug to Dr. Micallef on December 22, 2020.

SEC source: 0001078782-20-000610 · primary_doc.xml · derivative · entry 8

Micallef Jacob Vincent · CIK 0001651671 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 65,000 shares

Expires 2020-08-18

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001078782-20-000610 · primary_doc.xml · derivative · entry 7

Micallef Jacob Vincent · CIK 0001651671 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 65,000 shares

Expires 2020-08-18

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001078782-20-000610 · primary_doc.xml · nonDerivative · entry 4

Micallef Jacob Vincent · CIK 0001651671 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 100,928

F1 · shares: Represents the aggregate number of shares of common stock retained by VolitionRx for cancellation as payment of the exercise price in a cashless exercise and to satisfy the tax withholding obligations of the Reporting Person. No shares were sold by the Reporting Person or VolitionRx in such cashless exercise transaction.

SEC source: 0001078782-20-000610 · primary_doc.xml · nonDerivative · entry 3

Micallef Jacob Vincent · CIK 0001651671 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 161,008

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001078782-20-000610 · primary_doc.xml · nonDerivative · entry 2

Micallef Jacob Vincent · CIK 0001651671 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 96,008

F1 · shares: Represents the aggregate number of shares of common stock retained by VolitionRx for cancellation as payment of the exercise price in a cashless exercise and to satisfy the tax withholding obligations of the Reporting Person. No shares were sold by the Reporting Person or VolitionRx in such cashless exercise transaction.